Brian Park, PharmD, Author at Cancer Therapy Advisor
Brian Park, PharmD

Brian Park, PharmD

Drug Information Specialist https://www.cancertherapyadvisor.com
Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

Tucatinib Gets Priority Review for Locally Advanced or Metastatic HER2-Positive Breast Cancer

The FDA has accepted for Priority Review the New Drug Application (NDA) for tucatinib (Seattle Genetics), in combination with trastuzumab and capecitabine, for the treatment of patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received at least 3 prior HER2-directed agents separately or in combination, in the neoadjuvant, adjuvant or metastatic setting.

Next post in General Oncology